Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...

Geoffrey Shouse, DO, PhD, discusses what motivated this retrospective review of bispecific antibodies in diffuse large B-cell lymphoma at City of Hope.

Lyell Immunopharma (LYEL) announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy, RMAT, ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

Allogene Therapeutics, Inc.’s ALLO share price has surged by 6.64%, which has investors questioning if this is right time to ...

Roche RHHBY announced that the European Commission has approved its lymphoma drug, Columvi (glofitamab), for second-line ...

Basel: Roche has announced that the company has received approval from the European Commission for Columvi (glofitamab) in ...

In this interview, Magdalena Corona de Lapuerta, recipient of the Jian-Jian Luan Award for Lymphoma Transplant Research, ...

Roche (RHHBY) announced that the European Commission, EC, has approved Columvi in combination with gemcitabine and oxaliplatin for the ...

This Columvi regimen offers a much needed off-the-shelf and fixed-duration treatment option for those ineligible for transplant Basel, 14 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ...

Lucas Pacheco, a 18-year-old lymphoma survivor, fulfilled his dream of attending The Masters through the 'Make-A-Wish' ...